1 active not recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow AZD0171: new trials by email Literature Review of AZD0171 trials Research Report on AZD0171
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 630 | 2022-04-14 | 2026-10-21 |
| Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours AZD0171, Durvalumab, Gemcitabine - Locally Advanced or Metastatic Solid Tumours | Phase 2 | Active not recruiting | AstraZeneca | 126 | 2021-12-10 | 2026-08-19 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
AstraZeneca (2)
Canada (2) · South Korea (2) · Spain (2) · United States (2) · Belgium (1) · France (1) · Hungary (1) · Ireland (1) · Italy (1) · Portugal (1) · Taiwan (1) · Turkey (Türkiye) (1)
Tina Cascone, MD (1)
2023 (1)